Statistics for Rigel Pharmaceuticals (id:8239 RIGL)
Valuation metrics
Market cap
458.69M
Enterprise value
480.18M
Trailing P/E (ttm)
96.44
Forward P/E
29.59
PEG ratio
29.59
Price/Sales (ttm)
2.91
Price/Book (mrq)
-31.31
Enterprise Value/Revenue
3.05
Enterprise Value/EBITDA
42.42
Overview
Shares outstanding
17.62M
Float
14.75M
Shares short
661.19K
% Held by insiders
0.02%
% Held by institutions
0.68%
Average volume (10 days)
351.88K
Average volume (90 days)
Price summary
52-Week low
7.48
52-Week high
29.82
52-Week change
61.98%
Beta
0.95
50-Day moving average
16.94
200-Day moving average
12.82
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
Ex-dividend date
Last split factor
2:1
Last split date
June 27th, 2024
Financials
Fiscal yearFiscal year ends
December 31th, 2023
Most recent quarter (mrq)
September 30th, 2024
Profitability
Profit margin
2.47%
Operating margin
25.42%
Operational effectiveness
Return on assets
4.61%
Return on equity
87.60%
Income statement
Revenue (ttm)
8.98
Revenue per share (ttm)
8.98
Quarterly revenue growth (yoy)
Gross profit (ttm)
109.77M
EBITDA
11.32M
Net income to common (ttm)
3.88M
Diluted EPS (ttm)
0.27
Quarterly earnings growth (yoy)
Balance sheet
Total cash (mrq)
61.11M
Total cash per share (mrq)
3.47
Total debt (mrq)
100.21M
Total Debt/Equity (mrq)
-6.85
Current ratio (mrq)
196.00%
Book value per share (mrq)
-0.83
Cash flow
Cash flow statement
10.73M
Levered free cash flow (LFCF)
13.14M